Additional drugs that are being investigated for use in the treatment of human metabolic syndrome reduce ER stress by increasing endogenous chaperone expression (GLP-1 receptor agonists) or by serving as chemical chaperones (4-phenylbutyric acid and tauroursodeoxycholic acid (TUDCA)) [63]. Here, GLP1R is linked to metabolic syndrome.